16.35 0.00 (0.00%)
After hours: 4:34PM EST
|Bid||15.35 x 800|
|Ask||20.49 x 1100|
|Day's Range||15.82 - 16.59|
|52 Week Range||5.23 - 16.62|
|Beta (3Y Monthly)||-1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.67|
Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 21st Annual Needham Growth Conference in New York City on Tuesday, January 15, 2019 at 8:40 a.m.
The deal gives Veracyte $5 million up front, with an additional $15 million based on hitting certain milestones, and access to clinical data from more than 5,000 patients.
Veracyte, Inc. (“Veracyte”) (VCYT) announced today that it has entered into a long-term strategic collaboration with Johnson & Johnson Innovation LLC* and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. The collaboration will build upon foundational "field of injury" science -- where genomic changes associated with lung cancer can be identified with a simple brushing of a person's airway -- to develop new interventions that can save lives.
Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:30 a.m.
Veracyte, Inc. (VCYT) today announced that 20 medical centers across the United States are now offering the Envisia Genomic Classifier through an Early Access Program (EAP) to patients who are undergoing evaluation for interstitial lung diseases (ILD), including idiopathic pulmonary fibrosis (IPF). The program, launched in May 2018, provides advance access to the Envisia classifier, which the company anticipates making available nationwide in 2019.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018, at 9:00 a.m.
Veracyte, Inc. (VCYT) announced today the publication of “real world” data showing that the Afirma® Genomic Sequencing Classifier (GSC) enables even more patients to avoid unnecessary surgery in thyroid cancer diagnosis compared to the company’s flagship, original Afirma Gene Expression Classifier (GEC). In the study, researchers from Memorial Healthcare System in Hollywood, Fla., reviewed data from all patients in their practice whose thyroid nodules were deemed indeterminate (i.e., not clearly benign or cancerous) by cytopathology review and who subsequently received results from genomic testing with the Afirma GSC (n=139) or the Afirma GEC (n=481).
Veracyte (VCYT) has increased its revenue guidance for 2018 to the range of $90.0 million–$91.0 million from its previous guidance of $87.0 million–$89.0 million.
Veracyte (VCYT) generated revenue of $23.5 million in the third quarter compared to $17.5 million in the same period of the previous year, reflecting a ~34% YoY (year-over-year) rise. Veracyte generated net revenue of $66.3 million in the first nine months of the year compared to $52.4 million in the same period of the previous year, reflecting a rise of ~27% YoY. Veracyte’s revenue growth could boost the share price of the Invesco Russell 2000 Pure Growth ETF (PXSG).
Veracyte (VCYT) stock rose 22.46% on October 30 after it released its third-quarter earnings results on October 29. On October 30, Veracyte stock closed at $11.56, a ~22.46% rise from its previous day’s close of $9.44 on October 29.
CORAL GABLES, FL / ACCESSWIRE / October 31,2018 / Institutional investors' focus onhealthcare services has grown over the last several quarters. "Institutional investors have been learning from their experience and will likely be using those lessons as they inject hundreds of billions in capital into healthcare in the next five years. As these trends continue to foster investment, companies like Premier Health Group, Inc. (PHGRF) (PHGI.CN), Aeterna Zentaris Inc. (AEZS)(TSX:AEZS.TO) and Veracyte, Inc. (VCYT) could be positioned to capitalize on this growth.
Veracyte (VCYT) delivered earnings and revenue surprises of 50.00% and 9.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of 12 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by ...
Veracyte (NASDAQ: VCYT ) unveils its next round of earnings this Monday, Oct. 29. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement Earnings and Revenue Analysts covering ...
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veracyte, Inc. will release its third quarter 2018 financial results after the close of market on Monday, October 29, 2018. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m.
Veracyte, Inc. (VCYT) announced that new interim data from a three-year, “real world,” prospective clinical utility study show that use of the Percepta Bronchial Genomic Classifier to evaluate patients with potentially cancerous lung nodules reduced invasive procedures during 12 months of patient follow-up. The ongoing 40-site registry trial aims to measure the impact of the Percepta test on lung nodule management in “real world” clinical practice and to monitor clinical outcomes of patients managed with the test. Reviewing results from the first 258 evaluable patients, researchers found that patients who had a negative Percepta result following an inconclusive bronchoscopy had lower rates of subsequent invasive procedures at all evaluation time points (immediately post-test, 3 months, 6 months and 12 months), compared to physicians’ plans for these patients prior to Percepta testing.
Veracyte, Inc. (VCYT) announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery. Using data from a prospective study of 49 patients presenting with new-onset ILD, researchers evaluated samples obtained through nonsurgical transbronchial biopsy to determine the Envisia classifier’s accuracy in detecting usual interstitial pneumonia (UIP), a pattern whose presence is essential to IPF diagnosis.
Veracyte, Inc. (VCYT) announced today that new findings from six studies reinforcing the “real world” performance of the next-generation Afirma Genomic Sequencing Classifier (GSC) and the Afirma Xpression Atlas in thyroid cancer diagnosis were presented at the 88th Annual Meeting of the American Thyroid Association (ATA). Researchers from leading institutions presented posters showing that use of the Afirma GSC at their respective centers significantly increased the identification of benign thyroid nodules among those deemed indeterminate – not clearly benign or malignant – following cytopathology review, compared to the original Afirma test. The Ohio State University – Researchers compared results of 113 indeterminate samples that were tested with the Afirma GSC to those of 403 samples using the earlier version of the test (the Afirma Gene Expression Classifier, or GEC).
San Francisco, CA, based Investment company Versant Venture Management, LLC buys Veracyte Inc during the 3-months ended 2018-09-30, according to the most recent filings of the investment company, Versant ...
Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018, at 1:05 p.m.